<DOC>
	<DOCNO>NCT00857428</DOCNO>
	<brief_summary>The purpose study demonstrate relative bioequivalence oxymorphone hydrochloride extended-release tablet ( Sandoz ) Opana extend release oxymorphone hydrochloride tablet .</brief_summary>
	<brief_title>Bioavailability Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fasted Conditions</brief_title>
	<detailed_description>Bioequivalence base FDA Criteria .</detailed_description>
	<mesh_term>Oxymorphone</mesh_term>
	<criteria>No clinically significant abnormal finding physical exam , medical history clinical laboratory result screen . Positive test result HIV hepatitis B C Treatment drug alcohol dependence</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2009</verification_date>
</DOC>